STAT Plus: Acadia Pharmaceuticals buys pain drug maker, part of effort to expand on psychosis treatment
Acadia Pharmaceuticals is purchasing a small Texas startup, CerSci, for $52 million in order to acquire a pain drug in the early stages of development, the company said Tuesday.
If the drug succeeds, CerSci could receive an additional $887 payments for hitting commercial and development milestones.
